For the quarter ended December 2024, Archer Daniels Midland (ADM) reported income of $21.5 billion, down 6.4% over the identical interval final yr. EPS got here in at $1.14, in comparison with $1.36 within the year-ago quarter.
The reported income compares to the Zacks Consensus Estimate of $21.93 billion, representing a shock of -1.95%. The corporate delivered an EPS shock of +6.54%, with the consensus EPS estimate being $1.07.
Whereas buyers scrutinize income and earnings modifications year-over-year and the way they examine with Wall Avenue expectations to find out their subsequent transfer, some key metrics all the time provide a extra correct image of an organization’s monetary well being.
As these metrics affect top- and bottom-line efficiency, evaluating them to the year-ago numbers and what analysts estimated helps buyers venture a inventory’s worth efficiency extra precisely.
Right here is how ADM carried out within the simply reported quarter when it comes to the metrics most generally monitored and projected by Wall Avenue analysts:
- Processed volumes – Oilseeds: 9,050 Kmt versus the two-analyst common estimate of 9,503.66 Kmt.
- Revenues- Carbohydrate Options: $2.75 billion in comparison with the $2.38 billion common estimate primarily based on three analysts. The reported quantity represents a change of +4.5% yr over yr.
- Revenues- Different Enterprise: $100 million versus $106.07 million estimated by three analysts on common. In comparison with the year-ago quarter, this quantity represents a -2% change.
- Revenues- Vitamin: $1.77 billion versus the two-analyst common estimate of $1.72 billion. The reported quantity represents a year-over-year change of +3.1%.
- Revenues- Ag Companies and Oilseeds: $16.87 billion in comparison with the $17.21 billion common estimate primarily based on two analysts. The reported quantity represents a change of -8.9% yr over yr.
- Adjusted Section working profit- Carbohydrate Options- Whole: $319 million in comparison with the $313.80 million common estimate primarily based on two analysts.
- Adjusted Section working profit- Vitamin- Whole: $88 million versus the two-analyst common estimate of $85.31 million.
- Adjusted Section working profit- Vitamin- Animal Vitamin: $26 million versus $15.42 million estimated by two analysts on common.
- Adjusted Section Working Revenue (Loss)- Ag Companies and Oilseeds- Whole: $644 million in comparison with the $630.12 million common estimate primarily based on two analysts.
- Adjusted Section Working Revenue (Loss)- Ag Companies and Oilseeds- Ag Companies: $254 million in comparison with the $168.19 million common estimate primarily based on two analysts.
- Adjusted Section Working Revenue (Loss)- Different Enterprise: $47 million versus the two-analyst common estimate of $82.50 million.
- Adjusted Section Working Revenue (Loss)- Ag Companies and Oilseeds- Refined Merchandise and Different: $121 million versus $121.62 million estimated by two analysts on common.
View all Key Company Metrics for ADM here>>>
Shares of ADM have returned +0.8% over the previous month versus the Zacks S&P 500 composite’s +1% change. The inventory at present has a Zacks Rank #1 (Robust Purchase), indicating that it may outperform the broader market within the close to time period.
Analysis Chief Names “Single Greatest Decide to Double”
From hundreds of shares, 5 Zacks consultants every have chosen their favourite to skyrocket +100% or extra in months to come back. From these 5, Director of Analysis Sheraz Mian hand-picks one to have essentially the most explosive upside of all.
This firm targets millennial and Gen Z audiences, producing practically $1 billion in income final quarter alone. A latest pullback makes now a great time to leap aboard. After all, all our elite picks aren’t winners however this one may far surpass earlier Zacks’ Shares Set to Double like Nano-X Imaging which shot up +129.6% in little greater than 9 months.
Free: See Our Top Stock And 4 Runners Up
Archer Daniels Midland Company (ADM) : Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the creator and don’t essentially replicate these of Nasdaq, Inc.
